UA55668A - Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста - Google Patents
Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста Download PDFInfo
- Publication number
- UA55668A UA55668A UA2002042994A UA200242994A UA55668A UA 55668 A UA55668 A UA 55668A UA 2002042994 A UA2002042994 A UA 2002042994A UA 200242994 A UA200242994 A UA 200242994A UA 55668 A UA55668 A UA 55668A
- Authority
- UA
- Ukraine
- Prior art keywords
- stress
- blood pressure
- melatonin
- treating
- cardiovascular disorders
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 16
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 28
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003987 melatonin Drugs 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 210000000748 cardiovascular system Anatomy 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 abstract description 2
- 238000002651 drug therapy Methods 0.000 abstract 1
- 230000035882 stress Effects 0.000 description 34
- 230000036772 blood pressure Effects 0.000 description 20
- 230000033764 rhythmic process Effects 0.000 description 13
- 230000035487 diastolic blood pressure Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000035488 systolic blood pressure Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002996 emotional effect Effects 0.000 description 6
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000004560 pineal gland Anatomy 0.000 description 4
- 206010022998 Irritability Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 230000004617 sleep duration Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- XLGCMZLSEXRBSG-UHFFFAOYSA-N gidazepam Chemical compound N=1CC(=O)N(CC(=O)NN)C2=CC=C(Br)C=C2C=1C1=CC=CC=C1 XLGCMZLSEXRBSG-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста предусматривает применение медикаментозных средств. Перед кратковременным стрессовым событием или непосредственно при его возникновении внутрь принимают мелатонин. При большей длительности действия стрессового фактора мелатонин принимают перед отходом ко сну.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002042994A UA55668A (ru) | 2002-04-12 | 2002-04-12 | Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002042994A UA55668A (ru) | 2002-04-12 | 2002-04-12 | Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA55668A true UA55668A (ru) | 2003-04-15 |
Family
ID=74207126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002042994A UA55668A (ru) | 2002-04-12 | 2002-04-12 | Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA55668A (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179122B2 (en) | 2011-09-16 | 2019-01-15 | Darius Rassoulian | Use of melatonin |
-
2002
- 2002-04-12 UA UA2002042994A patent/UA55668A/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179122B2 (en) | 2011-09-16 | 2019-01-15 | Darius Rassoulian | Use of melatonin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hayano et al. | Hypothesis: respiratory sinus arrhythmia is an intrinsic resting function of cardiopulmonary system | |
| Restrick et al. | Assessment and follow up of patients prescribed long term oxygen treatment. | |
| US20220096417A1 (en) | Induction of arteriogenesis with an no (nitric oxide) donor | |
| Adlan et al. | Acute hydrocortisone administration reduces cardiovagal baroreflex sensitivity and heart rate variability in young men | |
| Dokur et al. | Scorpion-related cardiomyopathy and acute pulmonary edema in a child who is stung by Leiurus abdullahbayrami | |
| Hine et al. | SOME ASPECTS OF THE HUMAN PHARMACOLOGY OF TETRA-ETHYLTHIURAMDISULPHIDE (ANTABUS)-ALCOHOL REACTIONS | |
| Manhem et al. | Plasma noradrenaline and blood pressure in hypothyroid patients: effect of gradual thyroxine treatment | |
| Petrushanko et al. | The special features of comprehensive treatment оf patients with generalized parodontitis in the background of coronary heart disease | |
| Brotherston et al. | Night calls: their frequency and nature in one general practice | |
| UA55668A (ru) | Способ лечения и предупреждения нарушений деятельности сердечно-сосудистой системы стрессового происхождения у людей пожилого возраста | |
| Maxwell et al. | Meprobamate in the treatment of stuttering | |
| Yumatov et al. | System Organization of the Relationship Between Emotional Stress and Sleep | |
| Lewis et al. | Myopathy after short term administration of procainamide. | |
| RU2479315C1 (ru) | Фитосбор для лечения подростков с лабильной артериальной гипертензией | |
| US20190365693A1 (en) | Induction of arteriogenesis | |
| RU2447909C2 (ru) | Способ лечения больных гипертонической болезнью в сочетании с хроническим психо-эмоциональным напряжением | |
| RU2340280C1 (ru) | Способ прогнозирования неадекватной седации при нейроаксиальной анестезии | |
| Wetterberg | Light therapy of depression; basal and clinical aspects | |
| RU2787802C1 (ru) | Способ лечения больных постковидным синдромом | |
| RU2734717C1 (ru) | Способ профилактики предоперационными аэробными физическими тренировками послеоперационных когнитивных расстройств у пациентов при коронарном шунтировании в условиях искусственного кровообращения | |
| Tan et al. | Effects of surgical anesthesia on postoperative cognitive function of elderly patients | |
| SU1766412A1 (ru) | Способ лечени хронической интоксикации акрилатами | |
| Donegà et al. | Reversible hyperthyroidism and cardiomyopathy caused by consumption of iodocasein | |
| RU2290927C1 (ru) | Коронароактивное антиишемическое и антиаритмическое средство | |
| Calma et al. | Mon-474 coexistence of thyroid dysgenesis and premature ovarian failure: a case report |